Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research.
Research in diagnosis, management, and therapy development, as well as development of standardized guidelines for upcoming studies need to be addressed in order to improve the prognosis of DFI patients.
Why condensing a study’s findings concise presentation, in an easily understood and digestible format is harder than it appears.
In order to increase the number of potentially successful clinical development projects in the microbiome space, it will be important to recognize standard drug development principles and global drug or biologic development requirements.
A CRO with deep therapeutic, regulatory and operational expertise facilitates the risk-assessment process by highlighting items within the protocol design that have the potential to impact overall risk levels. Identifying these risks and potential operational challenges early in the process is essential to the success of RBM later in the study.
Revised study now includes the opportunity to demonstrate the cardiac safety of a new drug by utilizing Exposure-QT response study data in dose escalation and other studies.
Planning and executing a clinical study for an orphan indication presents a unique set of challenges and considerations. In this webinar, Michelle Petersen, Medpace Clinical Trial Manager discusses successful strategies and best practices for addressing some of these including: unique methods to site selection and feasibility, successful recruitment/retention approaches, overview of common study execution needs, and optimal training and monitoring strategies.
In this webinar, Medpace discusses how patient-focused clinical trial design and collaborative approaches to site enrollment can accelerate clinical research. This presentation features a doctor from Cincinnati Children's Hospital Medical Center and a parent of a child with Duchenne muscular dystrophy.
With an established regulatory environment and a strong healthcare infrastructure, Latin America continues to grow as an advantageous landscape for conducting clinical research. Join Medpace experts Anibal Calmaggi, MD, Senior Medical Director, Infectious Diseases and Vaccines, and Wanda Dobrzanski, MD, Director Clinical Operations, Pediatric infectious diseases and Pharmaceutical medicine specialist, as they share their collective 36 years of experience in designing and managing clinical research in Latin America.
In this webinar, we explore four areas that can dramatically affect the cost and timelines of your clinical program and offer insight into elimination and control of these hidden landmines.
In this webinar, you’ll hear about exciting new advisory and managed disclosure services from TrialScope, including: compliance, policy and process assessments, as well as plain-language summaries, protocol registration, results posting, and redaction services.
Clinical Trials, the costliest stage in drug development, have much to benefit from leveraging the cloud to collaborate with partners and share views of key data trends and process metrics.
A hands-on approach provides significant advantages that can shorten drug development timelines and reduce development risk.
CRO manages multiple, complex statistical analysis deliverables for a program of studies, CDISC compliant outputs, and data pooling for NDA submission to the FDA with minimal sponsor oversight.
A specialized partner in Hematology and Oncology clinical development.
